Skip to main content
Home Startups Valenbio
ZumaTek, Inc.


Ventilator-associated pneumonia is a common complication of critical illness. When multidrug-resistant, Gram-negative pathogens are the cause of pneumonia, the illness is particularly difficult to treat. Zhou, Fowler, and Toone are developing a new antibiotic that kills bacteria by inhibiting a particular enzyme involved in the synthesis of the bacterial outer membrane. The DTRI funding will allow them to demonstrate the efficacy of this novel class of antibiotics against pathogens in mice, the next step in the journey of developing a new therapy.